Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
NCT00556439
Aortic Arch Syndromes, Aortic Diseases
Los Angeles, California, United States
View Trial DetailsNCT Number: NCT00315471
Takayasu's arteritis is a rare disorder that causes swelling and damage to the large arteries in the body, such as the aorta. In order to ensure proper treatment, measuring disease activity is critical. The purpose of this study is to establish new biological markers (biomarkers) to assess the severity of disease in people with Takayasu's arteritis.
Looking for future studies?
Notify MeAll sexes
Observational
St. Joseph's Healthcare, Hamilton, Ontario, Canada
Takayasu's arteritis is a chronic inflammatory condition that affects the aorta, the largest blood vessel in the body, and its branches. Inflammation causes segments of the vessels to become narrowed, blocked, or even stretched, possibly resulting in aneurysms. The disease is very rare but most commonly occurs in young Asian women. Symptoms may include arm pain with use, decreased or absent pulses, lightheadedness or dizziness, headaches, and visual disturbances. Many individuals with Takayasu' arteritis, however, have no apparent symptoms despite disease activity. Additionally, current tests used to measure vessel inflammation are considered unreliable and inconsistent. It is therefore very difficult to determine the extent of disease activity in a person with Takayasu's arteritis. This study will use novel scientific methods to establish new biomarkers that can be used to monitor disease activity in individuals with Takayasu's arteritis. These biomarkers may be used to help direct clinical care and assist in future drug development.
Study visits will occur monthly for the first year, then every 3 months thereafter for the remainder of the study. Blood and urine collection will occur at every visit. A physical examination, disease assessment, and review of medications will occur every 3 months; participants may also be asked to complete various questionnaires. Diagnostic testing, which may include chest radiograph, echocardiogram, magnetic resonance imaging, or angiography, will occur every 6 months. Tobacco, alcohol, and drug use will be assessed on a yearly basis. Participants may have additional study visits if a disease flare or disease-related complications occur during the study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Study completion
Time frame: Study completion.
University of Pennsylvania
Other
VCRC Longitudinal Protocol for Takayasu's Arteritis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00556439
Aortic Arch Syndromes, Aortic Diseases
Los Angeles, California, United States
View Trial DetailsNCT01795456
Aortic Arch Syndromes, Aortic Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT02476292
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Aortic Arch Syndromes
Tampa, Florida, United States
View Trial DetailsNCT01241305
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Aortic Arch Syndromes
Los Angeles, California, United States
View Trial Details